SITC 2024: Marengo's CEO Zhen Su discusses the first-in-human data for the company's lead program, Invikafusp Alfa

blonca9
Nov 9, 2024
1 min read

He describes how this dual T-cell agonist is designed to cause the expansion and reprogramming of TIL's in the body. Plus, an update on Marengo's partnerships with Ipsen and Gilead, and his take on key highlights from this year's SITC annual meeting.

Recent Posts

See All

AI News: Emeryville based Fauna Bio launched Fauna Brain, an AI platform that uses both internal and external data sets, and an analysis of the literature, to allow users to identify and score targets

AI News: Alameda based Infinimmune launched its GLIMPSE-1 antibody engineering platform that is based on a protein language model focused on native human antibody sequences

Draig Therapeutics launched from stealth today with a total of $140M investments to tackle neuropsych conditions. Co-Founder & Executive Chair Ruth McKernan tells the backstory and why she is excited

SITC 2024: Marengo's CEO Zhen Su discusses the first-in-human data for the company's lead program, Invikafusp Alfa

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight